Marina Baretti, MD, Johns Hopkins University School of Medicine, Baltimore, MD, discusses findings from a Phase II trial (NCT03250273) of entinostat with nivolumab in pre-treated patients with pancreatic ductal adenocarcinoma (PDAC). 27 evaluable patients were enrolled and the overall response rate, which was the primary endpoint, was not met. However, the therapeutic approach may provide promising responses in a group of patients with limited treatment options. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.